share_log

T2 Biosystems | 144: Notice of proposed sale of securities pursuant to Rule 144

T2 Biosystems | 144: Notice of proposed sale of securities pursuant to Rule 144

T2 Biosystems | 144：擬議出售證券
美股SEC公告 ·  09/13 22:36
牛牛AI助理已提取核心訊息
David B. Elsbree, a Director at T2 Biosystems, Inc., is set to sell 55 shares of the company's common stock with an aggregate market value of $132.5. The sale is scheduled for 09/13/2024. Elsbree acquired these shares through open market purchases and as compensation in the form of restricted stock units, with acquisition dates of 06/06/2017 and 06/25/2021, respectively. There have been no reported sales of securities by Elsbree in the past three months.
David B. Elsbree, a Director at T2 Biosystems, Inc., is set to sell 55 shares of the company's common stock with an aggregate market value of $132.5. The sale is scheduled for 09/13/2024. Elsbree acquired these shares through open market purchases and as compensation in the form of restricted stock units, with acquisition dates of 06/06/2017 and 06/25/2021, respectively. There have been no reported sales of securities by Elsbree in the past three months.
David b. Elsbree，T2 Biosystems, Inc.的一位董事，計劃賣出55股公司的普通股，市值總計132.5美元。該交易計劃於2024年09/13進行。Elsbree通過公開市場購買以及作爲受限股票單位的補償獲得這些股票，分別是2017年06/06和2021年06/25的收購日期。Elpsree在過去三個月內沒有報告出售證券。
David b. Elsbree，T2 Biosystems, Inc.的一位董事，計劃賣出55股公司的普通股，市值總計132.5美元。該交易計劃於2024年09/13進行。Elsbree通過公開市場購買以及作爲受限股票單位的補償獲得這些股票，分別是2017年06/06和2021年06/25的收購日期。Elpsree在過去三個月內沒有報告出售證券。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。